Skip to main content

Table 1 Clinicalpathological parameters of BTC case series

From: Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas

Sample Sex Age Origin TNM * Grade
1 M 75 GBC T3N0M0 2
2 M 72 ICC T3N1M0 3
3 F 48 ICC T3N0M0 3
4 M 46 ECC T3N1M0 3
5 M 70 ECC T3N1M0 3
6 M 74 ECC T3N1M0 3
7 M 69 ICC TxN1M1 3
8 M 47 ICC TxN1M1 2
9 F 50 ICC T1N0M0 2
10 M 67 ICC T3N0M0 2
11 M 50 ICC T2NxM0 3
12 F 54 GBC TxN1M1 2
13 M 73 ECC T3N0M0 3
14 M 64 ECC T3N0M0 2
15 M 53 ECC T3N0M0 2
16 M 63 ECC T4N0M0 2
17 F 57 ECC T3N2M0 3
18 M 74 ECC T2N1M0 3
19 M 69 ECC T2N0M0 1
20 M 68 GBC T2N0M0 2
21 M 66 ICC T3N1M0 3
22 M 64 ECC T2N0M0 3
23 F 75 GBC T3NxM0 3
24 M 72 ECC T3N1M0 2
25 F 66 ICC T4N1M0 3
26 F 70 ECC TxN1M0 1
27 F 71 GBC T2N1M0 3
28 F 78 GBC T2NxM0 3
29 F 60 ECC T3N1M0 3
30 F 51 GBC T3N1M0 2
31 F 41 ICC NA 3
32 F 69 GBC T2N1M0 3
33 F 84 GBC T2NxM0 3
34 M 83 GBC T2NxM0 3
35 M 56 GBC T2NxM0 3
36 F 61 ICC TxNxM1 3
37 F 72 ICC TxNxM0 3
38 F 69 GBC T3N0M0 3
39 M 52 ICC TxNxM0 3
40 M 67 ECC TxNxM0 2
41 M 66 ICC T3NxM0 3
42 F 53 ECC T3N1M0 2
43 M 68 ECC TxNxM0 3
44 F 73 ECC T2N0M0 2
45 F 55 GBC T4N1M0 3
46 M 53 ICC TxNxM1 3
47 M 66 ICC T3NxM0 3
48 F 53 ICC TxNxM0 3
49 M 67 ECC T4N1M0 2
  1. ICC: Intrahepatic cholangiocarcinoma; ECC: Extrahepatic cholangiocarcinoma; GBC: Gallbladder carcinoma, * TNM staging (see ref. [30])